Abstract
The latest Byondis investigative therapy that will soon enter Phase I or First-in-Human (FiH) study is also the company’s first immuno-oncology (IO) therapeutic, BYON4228. How and why it got there is the stuff that researchers’ dreams are made of. BYON4228 is a monoclonal antibody (mAb). A mAb is – per the US National Cancer Institute (NCI), “a type of protein that is made in the laboratory and can bind to certain targets in the body, such as antigens on the surface of cancer cells.” Monoclonal antibodies can be used to diagnose and treat many diseases, such as cancers. They can be used alone or to carry drugs, toxins, or radioactive substances directly to cancer cells
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
